Portfolio Category: Pharmaceuticals

Nucleic acid-cationic polymer compositions of matter. May be used for treatment of cancer of the liver and pancreas as well as over thirty other types of cancers.

Ayana Pharma develops liposome-based treatments for cancer. Ayana was formed to leverage the benefits of the anticancer drug Doxil, an FDA-approved liposomal nanodrug that has been used in the treatment of ovarian cancer, metastatic breast cancer, AIDS-related Kaposi’s sarcoma, and multiple myeloma. Co-founded by one of Doxil’s co-inventors, Professor Yechezkel Barenholz from the Hebrew University, the company is working to expand its treatment uses and efficacy while making it more readily available to address a range of conditions. Ayana has completed fundraising to support an abbreviated new drug application (ANDA), filing, and commercialization.

LipoMedix is a development-stage privately held company focused on the development of an innovative, safe and effective cancer therapy based on liposome delivery. The Company was established in order to advance the pharmaceutical and clinical development of a patented new chemical entity prodrug of mitomycin-C and its efficient delivery in liposomes to cancer-affected target organs. This formulation known as Promitil  – Pegylated Liposomal Mitomycin-C Prodrug (PL-MLP) – overcomes the problems associated with mitomycin-C toxicity and turn it into a state-of-the-art anti-cancer drug that will potentially become the therapy of choice in a variety of cancers, especially those derived from the gastrointestinal tract (stomach, pancreas, colorectal). The inventor and scientific founder, of LipoMedix is Prof. Alberto Gabizon of the Hebrew University – Shaare Zedek Medical Center who is also the co-inventor and co-developer of Doxil, (the first FDA-approved nano-drug in cancer therapy). As co-developer of Doxil® Prof. Gabizon is one of the few scientists intimately familiar with the successful development & commercialization process of liposomal drugs.

CollPlant is a regenerative and aesthetic medicine company developing innovative technologies and products for tissue regeneration and organ manufacturing. Our revolutionary plant-based technology is the only commercially viable technology for mass production of recombinant human Type I collagen (rhCollagen), which is identical to the collagen produced by the human body. This makes our rhCollagen the ideal building block for regenerative medicine. Leveraging on the unique properties of rhCollagen and biomaterial know-how, we are developing a pipeline of products aimed at 3D bioprinting of tissues and organs and medical aesthetics.

MCFC was established with the aim to eliminate the use of chemical insecticides by employing patented RF technology. It is a cost-effective, non-toxic and versatile solution that replaces the use of dangerous pesticides, making organic cannabis products safer. 

Cavos Biotech is an emerging genomic and data science company focusing on the development of novel drugs based on naturally occurring resistance mechanisms for various diseases. We are developing a multi-level genomic algorithm to uncover the genetic base of extraordinary cancer resistance found in specific, and across various animals. We harness the genomic and data revolution and use high resolution identification methods to uncover existing anti-cancer mechanisms, and novel drug targets, and to revolutionize the way by which drug targets are discovered and identified.

Viral diseases represent a serious health threat, exemplified by the recent COVID-19 pandemic. Moreover, viral diseases, such as Dengue, West Nile, and Zika fevers exact a particularly significant toll in the developing world. Relying on the results of two decades of research, ViroBlock plans to target and exploit a particular vulnerability in the viruses that cause these diseases: ion channels. Channels are critical components of the pathogen that enable it to regulate its salinity and acidity. Consequently, inhibiting such channels is a promising and validated route to curb viral infectivity. In particular, ViroBlock developed rapid screening approaches that can identify inhibitors from thousands of chemicals in a matter of weeks. Finally, focusing the screen on a library of approved drugs (repurposing) shortens the regulatory approval time dramatically, while lowering the risk.

Tissue Dynamics bionic microtissues are three dimensional human organoids embedded with electro optical sensors that provide critical insight into human-relevant mechanisms. These proprietary physiological models are powered by unprecedented AI & automation capabilities. 

SpliSense is an Israel-based company focused on transformative RNA-based treatments. Our pioneering platform harnesses Antisense Oligonucleotides (ASOs) for treatment of genetic diseases such as Cystic Fibrosis and pulmonary diseases. Our innovative approach targets unmet needs in pulmonary diseases. SpliSense aims to target the root cause of the disease, to overcome specific genetic mutations and restore protein function.